@conference{
author = "Despotović, Jovana",
year = "2023",
abstract = "Colorectal cancer (CRC) is a heterogeneous disease that ranks third and second globally in terms of incidence and mortality rates, respectively. Five-year survival of patients with CRC is approximately 90% if diagnosed in the early stages, and only 13% if the advance disease is present. About 25% of patients already have CRC metastases (mCRC) with the primary CRC diagnosis, while half of the patients will develop metastases with further disease progression. The most common organ in which CRC metastasizes is the liver (colorectal cancer liver metastasis, CRLM). Almost half of CRC patients will die due to complications caused by the presence of metastases, so it is extremely important to discover new therapeutic approaches, as well as prognostic and predictive biomarkers, in order to reduce such a high mortality rate.
In the era of personalized medicine, various treatment modalities are available to CRC and mCRC patients, including resective surgery, systemic chemotherapy, and novel targeted biologics, which significantly improved the outcome of CRC patients. The main goal of neoadjuvant systemic chemotherapy is to render currently unresectable disease amenable to resection. The standard cytotoxic drugs used in systemic chemotherapy for the treatment of CRC are: 5-fluorouracil (5-FU), oxaliplatin, and irinotecan applied as single agents or combined. It has been shown that the combination of systemic chemotherapy with targeted biological agents (e.g., bevacizumab which targets vascular endothelial growth factor) leads to a better therapy response compared to the use of systemic chemotherapy alone.
MicroRNA (miRNA) molecules belong to a large class of small regulatory non-coding single-stranded RNA molecules that exert negative post-transcriptional regulation of gene expression. MiRNAs are involved in the regulation of fundamental cellular processes such as cell proliferation, differentiation and death, thus these molecules have been proposed as one of the regulators of oncogenesis, considering that they can have an oncogenic or tumor-suppressive role, which can be tumor-specific. The miRNA expression pattern is consistently and reproducibly altered in CRC compared with normal intestinal mucosa, and this expression pattern changes during the progression from normal colon, through adenoma to colorectal cancer. Not surprisingly, microRNAs have been implicated in the CRC growth, progression, metastasis, and response to therapy. MiRNAs have also been studied as potential diagnostic, prognostic and predictive biomarkers, and therapeutic agents or targets. To date, a small number of molecular biomarkers have been identified that can predict patient's response to therapy and thus help doctors in decision making to select the right therapy for a given patient. Identification of new validated predictive and prognostic biomarkers will be necessary to improve the quality of life and outcome of CRC patients. Hsa-miR-93-5p, together with hsa-miR-106b and hsa-miR-25, belongs to the miR-106b-25 cluster located on the 515 bp long region of chromosome 7q22, within intron 13 of the MCM7 gene. Interestingly, hsa-miR-93-5p has been reported to have oncogenic and tumor-suppressive roles in different tumor types.
This systematic review aims to present the current knowledge on the role of hsa-miR-93-5p in the processes related to colorectal carcinogenesis, metastasis, and response to chemotherapy in patients with primary and metastatic colorectal cancer. Also, the role of hsa-miR-93-5p as a potential prognostic and predictive biomarker is described.",
publisher = "Belgrade : Serbian Association on for Cancer Research",
journal = "6th Congress of the Serbian Association on for Cancer Research (SDIR)",
title = "Good cop-bad cop: different roles of hsa-miR-93-5p in colorectal cancer",
pages = "33-31",
number = "1",
url = "https://hdl.handle.net/21.15107/rcub_imagine_2097"
}